Engagement of B7 ligands, notably B7-1 (CD80) and B7-2 (CD86), on antigen-presenting cells with CD28 co-stimulatory receptors on T cells stimulates the proliferation and activation of CTLs, which subsequently elicits an anti-tumor immune response in the host. This evidence concerns the gene CD86 and neoplasm.